Mytocel MSKUnited Kingdom
Menu

UK supply, training and clinic support by Actomed

Bring point-of-care autologous micrografting to your clinic.

Mytocel MSK® combines a cartilage-derived autologous sample, controlled mechanical processing and a documented professional pathway.

04
Documented stages
~30
Minute workflow
09
Publications indexed
Runner in motion, representing active movement

Tissue in.
AMT® solution out.

01UK product supply

02Clinic onboarding

03Professional training

04First-case support

Why clinics assess Mytocel MSK

A specialist pathway designed around the point of care.

Mytocel MSK uses a small autologous auricular-cartilage sample. Rigenera® technology mechanically prepares a heterogeneous, tissue-specific micrograft suspension for use in the same professional pathway.

Explore the technology
Illustrative representation of the tissue-derived cellular and extracellular-matrix components carried in the AMT suspension
01

Autologous

Prepared from the patient’s own tissue.

02

Cartilage-derived

A tissue-specific source retaining cellular and extracellular-matrix components.

03

Mechanical

Documented processing without laboratory expansion or enzymatic digestion.

04

Point of care

Sampling, preparation and administration in one controlled pathway.

The documented pathway

Four stages. One clinical workflow.

This is a professional orientation. Technique, patient selection, equipment and sterile-procedure detail belong in the current controlled protocol and formal training.

How the Mytocel MSK protocol works, in four steps: prepare and anaesthetise the ear, take a tiny tissue sample, prepare the micrograft solution, and inject it into the affected joint.
01

Prepare

Establish the sterile field and prepare the auricular donor area according to the professional protocol.

02

Sample

Obtain three small auricular-cartilage samples using the documented punch technique.

03

Process

Mechanically disaggregate the samples in Rigeneracons® RS and collect the AMT® suspension.

04

Administer

Administer the suspension to the target joint within the same professional pathway.

Professional preparation of the Rigeneracons device
Controlled preparation
Professional joint administration procedure
Professional administration
Rigenera N4SA processing machineRigeneracons RS sterile single-use device

The professional system

Reusable processing. Sterile single-use pathway.

The N4SA machine provides the calibrated rotational impulse for the documented processing stage. Rigeneracons® RS is the sterile, single-use device designed to mechanically disaggregate the tissue sample.

  • Defined processing cycle
  • 80 μm documented cut-off
  • Single-use sterile device
  • Room-temperature product storage in supplied documentation

Evidence, in context

Make the study design visible before the headline.

The supplied evidence base is promising but early. Human records are small and largely uncontrolled; mechanistic and pre-clinical work should not be presented as direct clinical efficacy.

Review all nine records

Three-year case series

Clinical scores and MRI measurements in knee chondropathy.

n=8 cohort3 years follow-upMRI assessment

The long follow-up is useful context; the very small uncontrolled design does not support broad comparative claims.

Prospective open-label

Ten-patient KOOS evaluation to six months.

Reported improvements require confirmation in larger, randomised research.

Uncontrolled pilot

Ten-patient KOOS, WOMAC and VAS evaluation.

Twelve-month pilot outcomes provide early clinical context, not comparative proof.

Clinic adoption

From first question to first case.

Actomed supports clinical teams in assessing the evidence, defining the correct setup, completing professional onboarding and maintaining supply.

  1. 01

    Professional discussion

    Clinical fit, evidence questions and clinic objectives.

  2. 02

    Pricing and configuration

    Reusable equipment, single-use devices and expected usage.

  3. 03

    Training and preparation

    Protocol orientation, setup and supporting documentation.

  4. 04

    First-case pathway

    Agree practical support and readiness before clinical use.

  5. 05

    Ongoing supply

    Straightforward consumables reordering and product support.

Practical questions

What clinics ask before adoption.

Detailed biological, protocol and patient-selection answers are available in the professional FAQ.

Open the resource library
+What does a new clinic need to get started?

The documented setup includes the processing machine, sterile single-use Rigeneracons® RS devices, protocol training and a defined list of standard clinical consumables. Actomed will confirm the current UK configuration and availability.

+Who is the website intended for?

The site is written for qualified healthcare professionals and clinical organisations assessing Mytocel MSK for professional use. It is not a patient self-diagnosis or direct-to-consumer sales service.

+What evidence is available?

The supplied library includes mechanistic and pre-clinical work alongside small human clinical reports. Each evidence record is labelled by design, population, follow-up and limitations.

+Can Actomed support the first case?

Clinic onboarding can include a professional introduction, protocol and equipment orientation, training arrangements and discussion of first-case support.

New to Mytocel MSK

Plan your clinic setup.

Request current UK pricing, equipment options, professional materials and onboarding information.

Existing clinic

Keep your supply moving.

Reorder single-use devices, ask about stock or arrange continuing product support.

Professional enquiries

Assess Mytocel MSK for your clinic.

Receive current UK pricing, the professional pack and a clear onboarding route from Actomed.